Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose FOLFIRI vs Standard-dose FOLFIRI or FOLFOX-6 in UGT1A1 Wild-type Advanced CRC
NCT03329183Phase 2Unknown
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Mar 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan in colorectal cancer (CRC), sponsored by Shanghai Changzheng Hospital. Status: unknown.
02
Drugs
irinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03329183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03329183.